https://www.pharmaradar360.com/article/two-biotech-names-on-josh-brown-s-best-stocks-list-are-making-meaningful-highs-t-2a3d7615a4a7aa78Pharma Surgeen2026-08-03T15:18:04.000ZTwo biotech names on Josh Brown's Best Stocks list are making meaningful highs this summerhttps://www.pharmaradar360.com/article/astrazeneca-shares-slump-after-400bn-bms-merger-rumours-71cf1f553cc60264Pharma Surgeen2026-08-03T15:17:31.000ZAstraZeneca shares slump after $400bn BMS merger rumourshttps://www.pharmaradar360.com/article/astrazeneca-plc-stock-azn-moved-down-by-8-54-on-aug-3-key-drivers-unveiled-a1315ea5840d6c71Pharma Surgeen2026-08-03T15:15:24.000ZAstraZeneca PLC Stock (AZN) Moved Down by 8.54% on Aug 3: Key Drivers Unveiledhttps://www.pharmaradar360.com/article/decision-parallel-import-licences-granted-in-2026-0fd86ddc9d9dd737Pharma Surgeen2026-08-03T15:13:01.000ZDecision: Parallel import licences granted in 2026https://www.pharmaradar360.com/article/nice-recommends-heart-drug-aficamten-with-simultaneous-mhra-approval-465095fb0031d17ePharma Surgeen2026-08-03T15:12:16.000ZNICE recommends heart drug aficamten with simultaneous MHRA approvalhttps://www.pharmaradar360.com/article/digital-systems-in-general-practice-could-reduce-medication-errors-36fc9c338507e06aPharma Surgeen2026-08-03T15:10:47.000ZDigital systems in general practice could reduce medication errorshttps://www.pharmaradar360.com/article/notifiable-diseases-causative-agents-reports-for-2026-32900b46450305d4Pharma Surgeen2026-08-03T14:50:08.000ZNotifiable diseases: causative agents reports for 2026https://www.pharmaradar360.com/article/ceruvia-raises-8-million-to-advance-phase-1-2-trial-of-cluster-headache-therapy-bd39e02ec519ab01Pharma Surgeen2026-08-03T14:31:34.000ZCeruvia Raises $8 Million to Advance Phase 1/2 Trial of Cluster Headache Therapyhttps://www.pharmaradar360.com/article/form-424b5-moleculin-biotech-inc-for-3-august-by-investing-com-86c334fc957b9dc9Pharma Surgeen2026-08-03T14:21:53.000ZForm 424B5 Moleculin Biotech Inc For: 3 August By Investing.comhttps://www.pharmaradar360.com/article/faq-pharma-s-july-31-tariff-deadline-has-passed-now-what-f6da3b14d1c67b12Pharma Surgeen2026-08-03T14:21:45.000ZFAQ: Pharma's July 31 Tariff Deadline Has Passed. Now What?https://www.pharmaradar360.com/article/era-pooling-project-to-support-compliance-with-new-environmental-requirements-246eccca54ca1a31Pharma Surgeen2026-08-03T14:07:06.000ZERA Pooling Project to support compliance with new environmental requirementshttps://www.pharmaradar360.com/article/ceruvia-raises-8-million-to-complete-integrated-phase-1-2-trial-of-proprietary-n-e5dc5c9f88eb5a49Pharma Surgeen2026-08-03T14:01:36.000ZCeruvia Raises $8 Million to Complete Integrated Phase 1/2 Trial of Proprietary Non-Hallucinogenic LSD Analog for Cluster Headachehttps://www.pharmaradar360.com/article/work-ethic-becomes-a-flashpoint-as-china-s-biotech-pace-quickens-327b4e72a5e30da2Pharma Surgeen2026-08-03T14:00:00.000ZWork ethic becomes a flashpoint as China’s biotech pace quickenshttps://www.pharmaradar360.com/article/altimmune-alt-begins-enrollment-in-phase-3-trial-amid-high-pri-88602a032bd6542fPharma Surgeen2026-08-03T13:50:44.000ZAltimmune (ALT) Begins Enrollment in Phase 3 Trial Amid High Prihttps://www.pharmaradar360.com/article/why-is-krystal-biotech-krys-dropping-7-0-983788c8610c0f04Pharma Surgeen2026-08-03T13:48:17.000ZWhy Is Krystal Biotech (KRYS) Dropping 7.0%?https://www.pharmaradar360.com/article/4-biotech-stocks-likely-to-outpace-q2-earnings-estimates-fa1656b88958295cPharma Surgeen2026-08-03T13:42:40.000Z4 Biotech Stocks Likely to Outpace Q2 Earnings Estimateshttps://www.pharmaradar360.com/article/acurx-receives-fda-guidance-on-single-phase-3-trial-pathway-34c2c0468046459aPharma Surgeen2026-08-03T13:39:40.000ZAcurx receives FDA guidance on single Phase 3 trial pathwayhttps://www.pharmaradar360.com/article/why-this-top-notch-trio-of-biotech-stocks-just-took-a-tumble-954524825f29c6c3Pharma Surgeen2026-08-03T13:36:00.000ZWhy This Top-Notch Trio Of Biotech Stocks Just Took A Tumblehttps://www.pharmaradar360.com/article/graham-heap-joins-campfield-as-r-d-president-to-advance-prifemilast-phase-2-prog-7b47cbab7c259741Pharma Surgeen2026-08-03T13:35:52.000ZGraham Heap Joins cAMPfield as R&D President to Advance Prifemilast Phase 2 Programhttps://www.pharmaradar360.com/article/biotech-peach-yogurt-whey-and-dragon-fruit-lychee-creatine-b30dc000d655df8fPharma Surgeen2026-08-03T13:26:00.000ZBioTech Peach Yogurt Whey and Dragon Fruit Lychee Creatinehttps://www.pharmaradar360.com/article/is-there-a-pharma-mega-merger-in-the-making-e85ff7eab7dd650bPharma Surgeen2026-08-03T13:23:25.000ZIs there a pharma mega-merger in the making?https://www.pharmaradar360.com/article/is-organizational-readiness-pharma-s-real-ai-barrier-in-2026-003f3d408126b3a1Pharma Surgeen2026-08-03T13:18:53.000ZIs Organizational Readiness Pharma's Real AI Barrier in 2026?https://www.pharmaradar360.com/article/blossomhill-eyes-112m-ipo-harvest-to-bankroll-potential-tagrisso-challenger-bd128eeea63c9ac6Pharma Surgeen2026-08-03T13:18:47.000ZBlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challengerhttps://www.pharmaradar360.com/article/biotech-giant-amgen-says-patient-data-stolen-from-third-party-cloud-systems-a56a54538055f5caPharma Surgeen2026-08-03T13:09:03.000ZBiotech giant Amgen says patient data stolen from third-party cloud systemshttps://www.pharmaradar360.com/article/sino-biological-launches-precisely-characterised-full-length-p-tau217-protein-f6b1fa32e972a688Pharma Surgeen2026-08-03T13:08:38.000ZSino Biological launches precisely characterised full-length p-Tau217 proteinhttps://www.pharmaradar360.com/article/fda-approves-long-lasting-otc-pain-reliever-combining-acetaminophen-and-naproxen-b705877d8a45bc85Pharma Surgeen2026-08-03T13:08:11.000ZFDA approves long-lasting OTC pain reliever combining acetaminophen and naproxenhttps://www.pharmaradar360.com/article/two-biotech-ipos-test-the-market-s-reopening-3a3fb6dfb4c4bbccPharma Surgeen2026-08-03T13:00:44.000ZTwo Biotech IPOs Test The Market’s Reopeninghttps://www.pharmaradar360.com/article/fda-effort-to-recall-tavneos-challenged-by-drug-maker-10c9ff45ff5850d1Pharma Surgeen2026-08-03T13:00:00.000ZFDA Effort to Recall Tavneos Challenged by Drug Makerhttps://www.pharmaradar360.com/article/codexis-appoints-david-butler-phd-to-strategic-advisory-board-175ecfa61d0ff464Pharma Surgeen2026-08-03T13:00:00.000ZCodexis Appoints David Butler, PhD, to Strategic Advisory Boardhttps://www.pharmaradar360.com/article/biontech-picks-sobi-ceo-oelkers-to-lead-as-founders-plot-new-mrna-biotech-91fcdaa33164ad01Pharma Surgeen2026-08-03T12:57:06.000ZBioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotechhttps://www.pharmaradar360.com/article/supreme-court-preserves-broad-access-to-abortion-drug-mifepristone-7f64cc35a1f5e3e3Pharma Surgeen2026-08-03T12:48:26.000ZSupreme Court preserves broad access to abortion drug mifepristonehttps://www.pharmaradar360.com/article/moleculin-biotech-reports-positive-pivotal-phase-2-3-trial-results-for-annamycin-74d085c35cffa9c8Pharma Surgeen2026-08-03T12:46:33.000ZMoleculin Biotech Reports Positive Pivotal Phase 2/3 Trial Results for Annamycin in AMLhttps://www.pharmaradar360.com/article/aim-immunotech-announces-final-dose-in-phase-2-duripanc-trial-ahead-of-schedule-918caf39ddaf10e9Pharma Surgeen2026-08-03T12:44:00.000ZAIM ImmunoTech Announces Final Dose in Phase 2 DURIPANC Trial Ahead of Schedule for Ampligen in Metastatic Pancreatic Cancerhttps://www.pharmaradar360.com/article/cadrenal-therapeutics-solidifies-multi-indication-strategy-for-cad-1005-in-cardi-63ad04f5c7f9fb05Pharma Surgeen2026-08-03T12:42:36.000ZCadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuationhttps://www.pharmaradar360.com/article/veru-to-report-fiscal-2026-third-quarter-financial-results-on-august-10th-fbb23b37f096fab0Pharma Surgeen2026-08-03T12:42:22.000ZVeru to Report Fiscal 2026 Third Quarter Financial Results on August 10thhttps://www.pharmaradar360.com/article/novartis-pluvicto-leaps-ahead-into-earlier-manifestation-of-prostate-cancer-ddb68ca4eb8bd819Pharma Surgeen2026-08-03T12:33:04.000ZNovartis' Pluvicto leaps ahead into earlier manifestation of prostate cancerhttps://www.pharmaradar360.com/article/krystal-biotech-releases-q2-2026-financial-results-1fcb8f05ce98ad36Pharma Surgeen2026-08-03T12:32:55.000ZKrystal Biotech Releases Q2 2026 Financial Resultshttps://www.pharmaradar360.com/article/china-biotech-giant-wuxi-apptec-sees-first-half-earnings-surge-amid-us-scrutiny-f26712cfbd4730e9Pharma Surgeen2026-08-03T12:30:14.000ZChina biotech giant Wuxi AppTec sees first-half earnings surge amid US scrutinyhttps://www.pharmaradar360.com/article/intelligent-bio-solutions-drug-screen-tested-against-hand-creams-and-dirt-d040f2aebaf77fa3Pharma Surgeen2026-08-03T12:30:00.000ZIntelligent Bio Solutions drug screen tested against hand creams and dirthttps://www.pharmaradar360.com/article/085165079a02f176Pharma Surgeen2026-08-03T12:29:11.000ZΣυμπερίληψη Ελλάδας στον κατάλογο χωρών αναφοράς του Αιγυπτιακού Οργανισμού Φαρμάκων.https://www.pharmaradar360.com/article/latigo-blossomhill-launch-us-ipos-as-biotech-listings-rebound-d99842670da15370Pharma Surgeen2026-08-03T12:25:21.000ZLatigo, BlossomHill launch US IPOs as biotech listings reboundhttps://www.pharmaradar360.com/article/candel-therapeutics-to-present-extended-data-from-phase-3-results-of-aglatimagen-24afe6340484539dPharma Surgeen2026-08-03T12:05:00.000ZCandel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026https://www.pharmaradar360.com/article/acurx-s-550-patient-trial-could-support-c-diff-treatment-recurrence-reduction-b12dce6ba0ef4606Pharma Surgeen2026-08-03T12:00:00.000ZAcurx's ~550-Patient Trial Could Support C. diff Treatment, Recurrence Reductionhttps://www.pharmaradar360.com/article/which-is-the-better-state-street-healthcare-etf-the-broad-xlv-or-the-biotech-xbi-53858f6d9de117baPharma Surgeen2026-08-03T11:58:34.000ZWhich Is the Better State Street Healthcare ETF: The Broad XLV or the Biotech XBI?https://www.pharmaradar360.com/article/fda-proposes-restrictions-on-compounding-popular-weight-loss-medications-view-tf-e62684f02fa8f59fPharma Surgeen2026-08-03T11:56:46.000ZFDA Proposes Restrictions on Compounding Popular Weight Loss Medications - View tFixTzV5Qhttps://www.pharmaradar360.com/article/us-biotech-firm-human-trials-for-covid-19-vaccine-could-be-held-in-israel-eaa46ab301853c65Pharma Surgeen2026-08-03T11:52:04.000ZUS biotech firm: Human trials for COVID-19 vaccine could be held in Israelhttps://www.pharmaradar360.com/article/who-launches-global-framework-to-decarbonise-pharma-sector-71e372a951aa5b83Pharma Surgeen2026-08-03T11:48:28.000ZWHO Launches Global Framework to Decarbonise Pharma Sectorhttps://www.pharmaradar360.com/article/helus-pharma-s-new-ceo-led-a-14-6b-sale-to-johnson-johnson-aebf7ab82766e1e8Pharma Surgeen2026-08-03T11:47:39.000ZHelus Pharma's New CEO Led a $14.6B Sale to Johnson & Johnsonhttps://www.pharmaradar360.com/article/lilly-s-olomorasib-receives-u-s-fda-s-breakthrough-therapy-designation-for-the-t-5795f7eaefe7a5d5Pharma Surgeen2026-08-03T11:45:00.000ZLilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancerhttps://www.pharmaradar360.com/article/zevra-therapeutics-announces-publication-of-four-year-real-world-data-from-u-s-e-8d04f4f7d91887ecPharma Surgeen2026-08-03T11:40:18.000ZZevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)https://www.pharmaradar360.com/article/krystal-biotech-stock-falls-7-on-revenue-miss-despite-earnings-beat-74cec4b4f86ab3afPharma Surgeen2026-08-03T11:40:00.000ZKrystal Biotech stock falls 7% on revenue miss despite earnings beathttps://www.pharmaradar360.com/article/bombay-hc-revokes-fda-suspension-of-navi-mumbai-hotel-considers-costs-over-delay-2b7d23ddbbb32343Pharma Surgeen2026-08-03T11:37:33.000ZBombay HC Revokes FDA Suspension Of Navi Mumbai Hotel, Considers Costs Over Delay Despite 100 Per Centhttps://www.pharmaradar360.com/article/biontech-appoints-guido-oelkers-as-new-chief-executive-officer-b0b578b67413c717Pharma Surgeen2026-08-03T11:34:50.000ZBioNTech appoints Guido Oelkers as new Chief Executive Officerhttps://www.pharmaradar360.com/article/earnings-call-transcript-concord-biotech-misses-q1-2026-estimates-fa7cfd88f3730f98Pharma Surgeen2026-08-03T11:25:53.000ZEarnings call transcript: Concord Biotech misses Q1 2026 estimateshttps://www.pharmaradar360.com/article/belite-bio-presents-updated-phase-3-data-on-oral-tinlarebant-for-stargardt-40efd445f854cd99Pharma Surgeen2026-08-03T11:24:06.000ZBelite Bio presents updated phase 3 data on oral tinlarebant for Stargardthttps://www.pharmaradar360.com/article/krystal-biotech-q2-net-income-product-revenue-rise-shares-down-pre-bell-ded21393db136993Pharma Surgeen2026-08-03T11:23:53.000ZKrystal Biotech Q2 Net Income, Product Revenue Rise; Shares Down Pre-Bellhttps://www.pharmaradar360.com/article/krystal-biotech-krys-q2-2026-earnings-810e347897bd0a77Pharma Surgeen2026-08-03T11:21:13.000ZKrystal Biotech (KRYS) Q2 2026 Earningshttps://www.pharmaradar360.com/article/ocular-therapeutix-reports-q2-2026-results-confirms-q4-2026-axpaxli-nda-submissi-aaa22de9efc013bdPharma Surgeen2026-08-03T11:15:00.000ZOcular Therapeutix Reports Q2 2026 Results, Confirms Q4 2026 AXPAXLI NDA Submission Plan for Wet AMDhttps://www.pharmaradar360.com/article/fda-approved-weight-loss-patch-is-it-a-myth-or-a-realistic-option-view-wfolto9h9-08e21991723d5594Pharma Surgeen2026-08-03T11:14:04.000ZFDA Approved Weight Loss Patch: Is It a Myth or a Realistic Option? - View wfOLTo9h9https://www.pharmaradar360.com/article/krystal-biotech-2q-2026-revenue-119-22m-eps-1-79-10-q-summary-7af38be3c21756ccPharma Surgeen2026-08-03T11:11:01.000ZKrystal Biotech 2Q 2026: Revenue $119.22M, EPS $1.79— 10-Q Summaryhttps://www.pharmaradar360.com/article/boletin-sobre-seguridad-de-medicamentos-de-uso-humano-junio-de-2026-56621e43adac5c9dPharma Surgeen2026-08-03T11:07:02.000ZBoletín sobre Seguridad de Medicamentos de Uso Humano. Junio de 2026https://www.pharmaradar360.com/article/krystal-biotech-q2-revenue-rises-to-119-2-million-on-vyjuvek-sales-9bef3aad3dc011afPharma Surgeen2026-08-03T11:06:00.000ZKrystal Biotech Q2 revenue rises to $119.2 million on VYJUVEK saleshttps://www.pharmaradar360.com/article/fda-weight-loss-approved-drugs-evidence-based-options-for-safe-sustainable-resul-1ebff0dae5cf63cdPharma Surgeen2026-08-03T11:06:00.000ZFDA Weight Loss Approved Drugs: Evidence-Based Options for Safe, Sustainable Results *9RAcMCjbF*https://www.pharmaradar360.com/article/krystal-biotech-inc-quarterly-earnings-report-d7222c92b676b434Pharma Surgeen2026-08-03T11:03:59.000ZKrystal Biotech, Inc. Quarterly Earnings Reporthttps://www.pharmaradar360.com/article/cho-perfusion-model-lifts-yield-by-letting-cellular-waste-build-up-fe00ab79e494052cPharma Surgeen2026-08-03T11:00:41.000ZCHO perfusion model lifts yield by letting cellular waste build uphttps://www.pharmaradar360.com/article/opus-genetics-expects-data-in-2027-from-one-time-gene-therapy-trial-a62c779573496a38Pharma Surgeen2026-08-03T11:00:00.000ZOpus Genetics expects data in 2027 from one-time gene therapy trialhttps://www.pharmaradar360.com/article/opus-genetics-completes-patient-enrollment-in-b4b3490596318758Pharma Surgeen2026-08-03T11:00:00.000ZOpus Genetics Completes Patient Enrollment inhttps://www.pharmaradar360.com/article/what-would-it-take-to-get-peptides-on-the-shelf-26d4aa295f81e662Pharma Surgeen2026-08-03T11:00:00.000ZWhat would it take to get peptides on the shelf?https://www.pharmaradar360.com/article/fda-panel-ignites-debate-over-controversial-peptide-treatments-d1f587474973c5eaPharma Surgeen2026-08-03T11:00:00.000ZFDA Panel Ignites Debate Over Controversial Peptide Treatmentshttps://www.pharmaradar360.com/article/tg-therapeutics-reports-second-quarter-2026-financial-results-and-raises-briumvi-9725a783c2c7ad04Pharma Surgeen2026-08-03T11:00:00.000ZTG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidancehttps://www.pharmaradar360.com/article/can-fite-launches-first-clinical-program-for-piclidenoson-in-the-rare-genetic-di-42e44a139109431bPharma Surgeen2026-08-03T11:00:00.000ZCan-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndromehttps://www.pharmaradar360.com/article/over-the-counter-weight-loss-medication-what-works-what-doesn-t-and-how-to-pick-fc88611383fe20c0Pharma Surgeen2026-08-03T10:51:26.000ZOver the Counter Weight Loss Medication: What Works, What Doesn’t, and How to Pick a Safe Option in 2026 *0oSGFEEPg*https://www.pharmaradar360.com/article/online-platform-agrees-to-stop-selling-glp-1-drugs-to-us-customers-4ae3a90e731acbc0Pharma Surgeen2026-08-03T10:46:16.000ZOnline platform agrees to stop selling GLP-1 drugs to US customershttps://www.pharmaradar360.com/article/harbour-biomed-and-kelun-biotech-receive-china-ind-approval-for-bispecific-asthm-28a8e2cb4af12ff1Pharma Surgeen2026-08-03T10:41:15.000ZHarbour BioMed and Kelun-Biotech receive China IND approval for bispecific asthma therapyhttps://www.pharmaradar360.com/article/ipo-news-ipo-winners-losers-biotech-soars-jersey-mike-s-misses-and-spacex-faces-cb66f2714c114056Pharma Surgeen2026-08-03T10:27:59.000ZIPO News - IPO Winners & Losers: Biotech Soars, Jersey Mike's Misses, and SpaceX Faces the Lockuphttps://www.pharmaradar360.com/article/administrative-government-s-restrictions-on-mifepristone-are-arbitrary-and-capri-b00bb6a7d0696d7cPharma Surgeen2026-08-03T10:22:51.000ZAdministrative – Government’s restrictions on mifepristone are arbitrary and capricioushttps://www.pharmaradar360.com/article/retatrutide-weight-loss-jacksonville-view-hburryuvy-6cad9a61f3b39513Pharma Surgeen2026-08-03T10:20:10.000ZRetatrutide Weight Loss Jacksonville - View HburRYuVYhttps://www.pharmaradar360.com/article/partnership-to-create-ai-chemical-data-ecosystem-057e7a3c68334cd4Pharma Surgeen2026-08-03T10:18:40.000ZPartnership to create AI chemical data ecosystemhttps://www.pharmaradar360.com/article/fda-approved-weight-loss-patch-what-it-is-and-why-it-matters-or-doesn-t-view-rwf-ff263f0155237b91Pharma Surgeen2026-08-03T10:17:12.000ZFDA Approved Weight Loss Patch: What It Is and Why It Matters (or Doesn't) - View rwF6IMi5Zhttps://www.pharmaradar360.com/article/exec-on-execs-china-s-rise-in-biotech-investment-f29778c1aa52fb7fPharma Surgeen2026-08-03T10:12:56.000ZExec on Execs: China's Rise in Biotech Investmenthttps://www.pharmaradar360.com/article/116-100-shares-in-teva-pharmaceutical-industries-ltd-teva-bought-by-militia-capi-2cf0259463e000b9Pharma Surgeen2026-08-03T10:00:24.000Z116,100 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Bought by Militia Capital Management LLChttps://www.pharmaradar360.com/article/varda-announces-biopharma-leader-mikael-dolsten-will-join-board-as-space-based-p-e4fb549a68f2d79cPharma Surgeen2026-08-03T10:00:00.000ZVarda Announces Biopharma Leader Mikael Dolsten will Join Board as Space-Based Pharmaceutical Manufacturing Accelerateshttps://www.pharmaradar360.com/article/this-next-gen-glp-1-is-blowing-up-the-black-market-economy-789b37562a6bdc5aPharma Surgeen2026-08-03T10:00:00.000ZThis Next-Gen GLP-1 Is Blowing Up the Black Market Economyhttps://www.pharmaradar360.com/article/south-africa-prepares-for-potential-new-adult-tb-vaccine-13e0094d65226d45Pharma Surgeen2026-08-03T09:54:26.000ZSouth Africa Prepares for Potential New Adult TB Vaccinehttps://www.pharmaradar360.com/article/jeol-launches-two-high-resolution-microscopes-14fa5a388e190348Pharma Surgeen2026-08-03T09:48:03.000ZJeol launches two high-resolution microscopeshttps://www.pharmaradar360.com/article/radiopharm-asx-rad-expands-clinical-momentum-with-positive-trial-updates-80d2bdd2128ddf12Pharma Surgeen2026-08-03T09:47:00.000ZRadiopharm (ASX:RAD) Expands Clinical Momentum with Positive Trial Updateshttps://www.pharmaradar360.com/article/what-will-health-and-social-care-look-like-under-andy-burnham-dba84f191db4b195Pharma Surgeen2026-08-03T09:42:17.000ZWhat will health and social care look like under Andy Burnham?https://www.pharmaradar360.com/article/retatrutide-weight-loss-price-what-it-costs-in-2026-and-why-it-matters-view-9ujq-c30d07bade28054cPharma Surgeen2026-08-03T09:24:02.000ZRetatrutide Weight Loss Price: What It Costs in 2026 and Why It Matters - View 9UjQdSwbZhttps://www.pharmaradar360.com/article/pharmaceutical-weight-loss-view-bueibwgjg-819e94458d985951Pharma Surgeen2026-08-03T09:14:09.000ZPharmaceutical Weight Loss - View BUEiBWgjghttps://www.pharmaradar360.com/article/impact-licenses-ovarian-cancer-drug-senaparib-to-pharmanovia-cdc5924972d68a16Pharma Surgeen2026-08-03T09:00:51.000ZIMPACT licenses ovarian cancer drug senaparib to Pharmanoviahttps://www.pharmaradar360.com/article/fda-approved-weight-loss-medications-list-view-uyywmxlnc-c60d3939fe7ba1a4Pharma Surgeen2026-08-03T08:58:28.000ZFDA Approved Weight Loss Medications List - View UYywmxlnchttps://www.pharmaradar360.com/article/unlocking-peptide-permeability-with-high-throughput-sfc-epsa-analysis-eb2c8abc5f6e24c6Pharma Surgeen2026-08-03T08:54:43.000ZUnlocking peptide permeability with high-throughput SFC-EPSA analysishttps://www.pharmaradar360.com/article/breast-cancer-trial-highlights-promise-and-risks-of-dual-immunotherapy-61f474a8f3b39983Pharma Surgeen2026-08-03T08:54:24.000ZBreast Cancer Trial Highlights Promise and Risks of Dual Immunotherapyhttps://www.pharmaradar360.com/article/billionaire-stanley-druckenmiller-bought-this-biotech-stock-that-has-surged-400-3e0951d9f0d4c95fPharma Surgeen2026-08-03T08:52:00.000ZBillionaire Stanley Druckenmiller Bought This Biotech Stock That Has Surged 400%. Is It Still a Buy?https://www.pharmaradar360.com/article/sven-borho-steps-down-from-worldwide-health-with-biotech-growth-s-hsu-becoming-c-cfa958a4e77a26b7Pharma Surgeen2026-08-03T08:48:04.000ZSven Borho steps down from Worldwide Health with Biotech Growth's Hsu becoming co-managerhttps://www.pharmaradar360.com/article/astrazeneca-and-bms-in-talks-over-major-pharmaceutical-merger-9bba81a2f5976adePharma Surgeen2026-08-03T08:47:52.000ZAstraZeneca And BMS In Talks Over Major Pharmaceutical Mergerhttps://www.pharmaradar360.com/article/regulatory-round-up-3-august-2026-317fac41e47f8f05Pharma Surgeen2026-08-03T08:45:47.000ZRegulatory round-up: 3 August 2026https://www.pharmaradar360.com/article/ractigen-wins-fda-ind-clearance-for-sarna-candidate-507244f35c63b056Pharma Surgeen2026-08-03T08:36:25.000ZRactigen wins FDA IND clearance for saRNA candidatehttps://www.pharmaradar360.com/article/astrazeneca-in-talks-to-create-300bn-pharmaceutical-giant-f730c2e4f3a0c6bePharma Surgeen2026-08-03T08:36:00.000ZAstraZeneca ‘in talks to create £300bn pharmaceutical giant’https://www.pharmaradar360.com/article/dongkook-pharm-nears-w1-trillion-sales-milestone-83545cfd7cd251cbPharma Surgeen2026-08-03T08:30:43.000ZDongkook Pharm Nears W1 Trillion Sales Milestonehttps://www.pharmaradar360.com/article/pneumococcal-polysaccharide-conjugate-vaccine-pcv20-pgd-template-e123e687bede1c8dPharma Surgeen2026-08-03T08:30:00.000ZPneumococcal polysaccharide conjugate vaccine (PCV20) PGD templatehttps://www.pharmaradar360.com/article/pcv-13-valent-or-15-valent-adsorbed-patient-group-direction-pgd-template-9f8a91512dbcc4ffPharma Surgeen2026-08-03T08:30:00.000ZPCV (13-valent or 15-valent, adsorbed): patient group direction (PGD) templatehttps://www.pharmaradar360.com/article/dhsc-privacy-notice-6199fbf5d25ab84cPharma Surgeen2026-08-03T08:30:00.000ZDHSC privacy noticehttps://www.pharmaradar360.com/article/department-of-health-and-social-care-record-of-processing-activity-ropa-0a8251143f475789Pharma Surgeen2026-08-03T08:30:00.000ZDepartment of Health and Social Care record of processing activity (RoPA)https://www.pharmaradar360.com/article/bcg-vaccine-ajv-patient-group-direction-pgd-template-d5eac209b6d2a75cPharma Surgeen2026-08-03T08:30:00.000ZBCG Vaccine AJV: patient group direction (PGD) templatehttps://www.pharmaradar360.com/article/billionaire-stanley-druckenmiller-bought-this-biotech-stock-that-has-surged-400-dcbf1871be4923ebPharma Surgeen2026-08-03T08:28:12.000ZBillionaire Stanley Druckenmiller Bought This Biotech Stock That Has Surged 400%. Is It Still a Buy?https://www.pharmaradar360.com/article/billionaire-stanley-druckenmiller-bought-this-biotech-stock-that-has-surged-400-8a0b6a5398969036Pharma Surgeen2026-08-03T08:12:00.000ZBillionaire Stanley Druckenmiller Bought This Biotech Stock That Has Surged 400%. Is It Still a Buy?https://www.pharmaradar360.com/article/south-africa-prepares-for-potential-breakthrough-adult-tb-vaccine-955197d00a68213fPharma Surgeen2026-08-03T07:52:27.000ZSouth Africa prepares for potential breakthrough adult TB vaccinehttps://www.pharmaradar360.com/article/media-astrazeneca-and-bristol-myers-hold-mega-merger-talks-d044c268337764d7Pharma Surgeen2026-08-03T07:48:54.000ZMedia: AstraZeneca and Bristol Myers hold mega-merger talkshttps://www.pharmaradar360.com/article/one-of-china-s-major-pharmaceutical-companies-joined-belarusian-stock-market-613188fcb9d89fdfPharma Surgeen2026-08-03T07:41:00.000ZOne of China’s major pharmaceutical companies joined Belarusian stock markethttps://www.pharmaradar360.com/article/dr-ram-sarma-joins-virchow-biotech-as-chief-operating-officer-bb17614545bc2ac2Pharma Surgeen2026-08-03T07:33:24.000ZDr. Ram Sarma Joins Virchow Biotech as Chief Operating Officerhttps://www.pharmaradar360.com/article/zeus-delivers-a-bolt-of-pain-to-novo-nordisk-25373ee3560d6041Pharma Surgeen2026-08-03T07:26:02.000ZZEUS delivers a bolt of pain to Novo Nordiskhttps://www.pharmaradar360.com/article/retatrutide-for-weight-loss-what-the-phase-3-data-really-shows-view-ykrggbybc-85d101fa5de3a181Pharma Surgeen2026-08-03T07:18:41.000ZRetatrutide for Weight Loss: What the Phase 3 Data Really Shows - View ykRgGbybchttps://www.pharmaradar360.com/article/astrazeneca-bristol-myers-squibb-discuss-mega-merger-73beab93d51c0a25Pharma Surgeen2026-08-03T07:15:52.000ZAstraZeneca, Bristol Myers Squibb Discuss Mega-Mergerhttps://www.pharmaradar360.com/article/weight-loss-pharmaceutical-drugs-what-they-are-how-they-work-and-realistic-expec-72bcdf182b59f4f2Pharma Surgeen2026-08-03T07:12:00.000ZWeight Loss Pharmaceutical Drugs: What They Are, How They Work, and Realistic Expectations *mp8ZQmYHf*https://www.pharmaradar360.com/article/investor-lawsuit-looms-lawyer-predicts-three-consequences-for-novo-nordisk-255f39fb9c951eb1Pharma Surgeen2026-08-03T07:09:00.000ZInvestor lawsuit looms: Lawyer predicts three consequences for Novo Nordiskhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-teva-shares-sold-by-amundi-f289585d0a1f2be8Pharma Surgeen2026-08-03T07:06:48.000ZTeva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Amundihttps://www.pharmaradar360.com/article/montana-s-new-right-to-try-opening-the-door-to-profit-from-unproven-drugs-ca59a447334f0593Pharma Surgeen2026-08-03T07:02:58.000ZMontana’s new “right to try”: Opening the door to profit from unproven drugshttps://www.pharmaradar360.com/article/sun-pharmaceutical-industries-shares-fall-2-in-early-trade-3b6dc738ffec22acPharma Surgeen2026-08-03T06:54:10.000ZSun Pharmaceutical Industries shares fall 2% in early tradehttps://www.pharmaradar360.com/article/mesoblast-s-ryoncil-posts-115m-first-year-revenue-on-pediatric-approval-e38c06a60eb4da14Pharma Surgeen2026-08-03T06:38:08.000ZMesoblast’s Ryoncil Posts $115M First-Year Revenue on Pediatric Approvalhttps://www.pharmaradar360.com/article/fda-advisory-no-2026-0861-public-health-warning-against-the-purchase-and-use-of-aa6977e3d44274f9Pharma Surgeen2026-08-03T06:36:29.000ZFDA Advisory No.2026-0861 || Public Health Warning Against the Purchase and Use of the Unregistered Drug Product “Tsunami® Plant Essence Herbal Recipe 15 g”https://www.pharmaradar360.com/article/jba-1852486ac95c696cPharma Surgeen2026-08-03T06:30:00.000Z公益財団法人日本バスケットボール協会（JBA）とのパートナー契約決定のお知らせhttps://www.pharmaradar360.com/article/announcement-of-partnership-with-the-japan-basketball-association-jba-b25a71238e74d58bPharma Surgeen2026-08-03T06:30:00.000ZAnnouncement of Partnership with the Japan Basketball Association (JBA)https://www.pharmaradar360.com/article/what-is-retatrutide-for-weight-loss-view-caaqswt8m-76220cded81dc1baPharma Surgeen2026-08-03T06:23:51.000ZWhat Is Retatrutide for Weight Loss? - View CAAQswt8mhttps://www.pharmaradar360.com/article/dr-reddy-s-rituximab-biosimilar-gets-approval-from-us-fda-b6a018bb37c23738Pharma Surgeen2026-08-03T06:22:07.000ZDr. Reddy's Rituximab biosimilar gets approval from US FDAhttps://www.pharmaradar360.com/article/concord-biotech-consolidated-profit-rises-43-7-in-q1fy26-249d19d0d23826bePharma Surgeen2026-08-03T06:15:57.000ZConcord Biotech consolidated profit rises 43.7% in Q1FY26https://www.pharmaradar360.com/article/alto-neuroscience-buy-alto-207-advancement-trd-and-other-expansion-indications-a-ed88996de6106136Pharma Surgeen2026-08-03T06:04:17.000ZAlto Neuroscience: Buy ALTO-207 Advancement TRD And Other Expansion Indications (ANRO)https://www.pharmaradar360.com/article/la-aemps-colabora-con-la-agencia-reguladora-de-ghana-para-fortalecer-sus-capacid-00b1e41c4a61a1cePharma Surgeen2026-08-03T06:00:08.000ZLa AEMPS colabora con la agencia reguladora de Ghana para fortalecer sus capacidades para la evaluación de medicamentos biológicoshttps://www.pharmaradar360.com/article/weight-loss-research-news-view-t4ylvlml1-b24227777c7877cbPharma Surgeen2026-08-03T05:35:17.000ZWeight Loss Research News - View t4yLvLml1https://www.pharmaradar360.com/article/is-stronger-q2-results-raised-outlook-and-buybacks-altering-the-investment-case-75b7be52c3122d6bPharma Surgeen2026-08-03T05:08:42.000ZIs Stronger Q2 Results, Raised Outlook and Buybacks Altering The Investment Case For West Pharmaceutical Services (WST)?https://www.pharmaradar360.com/article/gas-crisis-strikes-paracetamol-api-other-industries-03fc12f35536dfe1Pharma Surgeen2026-08-03T05:08:39.000ZGas crisis strikes paracetamol API, other industrieshttps://www.pharmaradar360.com/article/mumbai-rusted-metal-pin-allegedly-found-in-kaju-katli-bought-from-charni-roads-t-3fe4f7bfe72bb750Pharma Surgeen2026-08-03T05:08:17.000ZMumbai: Rusted Metal Pin Allegedly Found In Kaju Katli Bought From Charni Roads Tewari Bros Sweet Shop; Videohttps://www.pharmaradar360.com/article/viking-therapeutics-bionxt-solutions-and-bausch-health-clinical-success-sparks-f-00a525e6ed74d761Pharma Surgeen2026-08-03T05:07:46.000ZViking Therapeutics, BioNxt Solutions, and Bausch Health: Clinical Success Sparks Fresh Optimismhttps://www.pharmaradar360.com/article/botanix-pharmaceuticals-asx-bot-jumps-5-per-cent-on-a-single-tick-not-a-biotech-600ec24db9193bdePharma Surgeen2026-08-03T05:04:00.000ZBotanix Pharmaceuticals (ASX:BOT) – Jumps 5 Per Cent on a Single Tick, Not a Biotech Revivalhttps://www.pharmaradar360.com/article/can-irbesartan-cause-erectile-dysfunction-view-wnckv3rkn-71ec5e46213c4f03Pharma Surgeen2026-08-03T04:47:11.000ZCan Irbesartan Cause Erectile Dysfunction - View WnCkv3RKNhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-raised-guidance-is-the-upside-already-priced-in-7f982eece2cabac7Pharma Surgeen2026-08-03T04:32:00.000ZWest Pharmaceutical Services (WST) Raised Guidance, Is The Upside Already Priced In?https://www.pharmaradar360.com/article/kelun-biotech-receives-china-clearance-to-begin-clinical-development-of-dual-pay-807d665e6674bd69Pharma Surgeen2026-08-03T04:12:58.000ZKelun-Biotech receives China clearance to begin clinical development of dual-payload ADChttps://www.pharmaradar360.com/article/biotech-leaders-call-for-streamlining-of-inds-as-fda-s-trialblazer-rolls-out-3b83311b2a27e73fPharma Surgeen2026-08-03T04:10:57.000ZBiotech leaders call for streamlining of INDs as FDA’s Trialblazer rolls outhttps://www.pharmaradar360.com/article/5-companies-advancing-attr-assets-in-the-wake-of-wainua-s-fail-5f3e3d297990ff59Pharma Surgeen2026-08-03T04:10:57.000Z5 companies advancing ATTR assets in the wake of Wainua’s failhttps://www.pharmaradar360.com/article/texas-pickleball-is-blazing-hot-while-california-trim-clinic-says-peptides-are-t-c7433cbc0da72c91Pharma Surgeen2026-08-03T04:10:23.000ZTexas Pickleball Is Blazing Hot, While California Trim Clinic Says Peptides Are Turning Up the Heathttps://www.pharmaradar360.com/article/ltgo-ipo-news-pain-relief-biotech-latigo-biotherapeutics-sets-terms-for-272-mill-25a2284293c9b137Pharma Surgeen2026-08-03T04:00:00.000ZLTGO IPO News - Pain relief biotech Latigo Biotherapeutics sets terms for $272 million IPOhttps://www.pharmaradar360.com/article/blsm-ipo-news-cancer-biotech-blossomhill-therapeutics-sets-terms-for-125-million-4a6d751460f9e5e1Pharma Surgeen2026-08-03T04:00:00.000ZBLSM IPO News - Cancer biotech BlossomHill Therapeutics sets terms for $125 million IPOhttps://www.pharmaradar360.com/article/astrazeneca-bristol-myers-squibb-in-merger-talks-to-create-nearly-400-billion-ph-1b5457d3b64574ecPharma Surgeen2026-08-03T03:57:07.000ZAstraZeneca, Bristol Myers Squibb in Merger Talks to Create Nearly $400 Billion Pharma Gianthttps://www.pharmaradar360.com/article/how-china-s-innovative-pharmaceutical-industry-accelerates-with-reform-745e94de9c989340Pharma Surgeen2026-08-03T03:34:13.000ZHow China's innovative pharmaceutical industry accelerates with reformhttps://www.pharmaradar360.com/article/piramal-pharmas-quarterly-results-reflect-resilience-in-the-pharmaceutical-indus-d4b4fac3245a156bPharma Surgeen2026-08-03T03:11:28.000ZPiramal Pharmas Quarterly Results Reflect Resilience in the Pharmaceutical Industryhttps://www.pharmaradar360.com/article/shinsa-information-on-biosimilars-is-updated-4166254cb4a37a8aPharma Surgeen2026-08-03T03:00:00.000Z[SHINSA]Information on biosimilars is updatedhttps://www.pharmaradar360.com/article/biotech-stocks-need-a-shot-in-the-arm-after-brutal-july-could-astrazeneca-bristo-0c28c1010a46e800Pharma Surgeen2026-08-03T02:54:16.000ZBiotech Stocks Need A Shot In The Arm After Brutal July: Could AstraZeneca-Bristol Myers Megadeal Be The Cure?https://www.pharmaradar360.com/article/biotech-stocks-need-a-shot-in-the-arm-after-brutal-july-could-astrazeneca-bristo-e50080af1804cec4Pharma Surgeen2026-08-03T02:48:00.000ZBiotech Stocks Need A Shot In The Arm After Brutal July: Could AstraZeneca-Bristol Myers Megadeal Be The Cure?https://www.pharmaradar360.com/article/fauci-hearing-fact-check-part-iii-the-safety-claims-the-money-and-the-question-n-7cfbc937e01d2f6bPharma Surgeen2026-08-03T02:44:21.000ZFauci hearing fact-check - Part III - the safety claims, the money, and the question nobody answeredhttps://www.pharmaradar360.com/article/hlb-panagene-signs-exclusive-singapore-pna-supply-deal-with-roche-affiliated-res-b9c6cb4cebe69319Pharma Surgeen2026-08-03T02:25:00.000ZHLB Panagene Signs Exclusive Singapore PNA Supply Deal With Roche-Affiliated Research Institutehttps://www.pharmaradar360.com/article/cj-olive-young-expands-advanced-derma-line-with-pharmaceutical-partners-6a75e11b593eb6daPharma Surgeen2026-08-03T02:10:45.000ZCJ Olive Young expands 'Advanced Derma' line with pharmaceutical partnershttps://www.pharmaradar360.com/article/novo-nordisk-s-failed-heart-drug-trial-raises-the-stakes-for-wednesday-s-earning-b907360b5034137dPharma Surgeen2026-08-03T02:02:24.000ZNovo Nordisk's Failed Heart Drug Trial Raises the Stakes for Wednesday's Earningshttps://www.pharmaradar360.com/article/pharmac-to-refresh-patient-advisory-function-c55da6f2b5960b4cPharma Surgeen2026-08-03T02:00:00.000ZPharmac to refresh patient advisory functionhttps://www.pharmaradar360.com/article/ono-pharmaceutical-fy2026-q1-earnings-call-core-operating-profit-up-22-5-to-38-7-7d71b1a12d5a82d0Pharma Surgeen2026-08-03T01:46:00.000Z【Ono Pharmaceutical FY2026 Q1 Earnings Call】Core Operating Profit Up 22.5% to ¥38.7 Billion; Overseas Sales and Royalties Drive Post-Forxiga Revenue Structure, Upside Potential from Weak Yenhttps://www.pharmaradar360.com/article/salmonella-outbreak-tied-to-major-egg-recall-as-nearly-one-hundred-fall-ill-acro-e2f996c895994692Pharma Surgeen2026-08-03T01:38:44.000ZSalmonella Outbreak Tied To Major Egg Recall As Nearly One Hundred Fall Ill Across Seventeen US Stateshttps://www.pharmaradar360.com/article/philippine-consulate-attends-biotech-and-beyond-speaker-series-featuring-thermo-87948c0a498ecd0bPharma Surgeen2026-08-03T01:14:59.000ZPhilippine Consulate Attends Biotech and Beyond Speaker Series Featuring Thermo Fisher Scientifichttps://www.pharmaradar360.com/article/sumitomo-pharma-announces-personnel-change-2fa783b9fbc80194Pharma Surgeen2026-08-03T01:00:00.000ZSumitomo Pharma Announces Personnel Changehttps://www.pharmaradar360.com/article/this-biotech-stock-nearly-doubled-in-value-today-morning-what-s-driving-investor-2b6d85a1f88a0aebPharma Surgeen2026-08-03T00:25:27.000ZThis Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism?https://www.pharmaradar360.com/article/sfda-approves-first-daily-oral-weight-loss-drug-for-adults-with-obesity-05dfa119b37f0dc2Pharma Surgeen2026-08-03T00:23:00.000ZSFDA approves first daily oral weight-loss drug for adults with obesityhttps://www.pharmaradar360.com/article/fujifilm-and-taiho-pharmaceutical-enter-into-strategic-partnership-for-developme-d35ba8df72551131Pharma Surgeen2026-08-03T00:00:00.000ZFujifilm and Taiho Pharmaceutical Enter into Strategic Partnership for Development of Next-Generation Antibody-Drug Conjugate (ADC) Manufacturing Technologies Optimizing Manufacturing Processes to Enable Stable Production of High-Quality ADCshttps://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-9716ef9a6136dea2Pharma Surgeen2026-08-03T00:00:00.000ZAstraZeneca filed Form 6-Khttps://www.pharmaradar360.com/article/biontech-filed-form-6-k-713dbf8e72538916Pharma Surgeen2026-08-03T00:00:00.000ZBioNTech filed Form 6-Khttps://www.pharmaradar360.com/article/gsk-filed-form-6-k-6c990fdae65d7317Pharma Surgeen2026-08-03T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/publication-of-sustainability-report-2026-ddc2615ce892b29aPharma Surgeen2026-08-03T00:00:00.000ZPublication of Sustainability Report 2026https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-325f397305d974a1Pharma Surgeen2026-08-03T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-594a38c56dc3919aPharma Surgeen2026-08-03T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-3d751053fc96f00bPharma Surgeen2026-08-03T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-2bca36375a4717baPharma Surgeen2026-08-03T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-21283b5f956edc2cPharma Surgeen2026-08-03T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-50b70b3071fc451aPharma Surgeen2026-08-03T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-3dd86914a7bf7247Pharma Surgeen2026-08-03T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-b20ba48e7eabe3ddPharma Surgeen2026-08-03T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-fd3e20d928ca0167Pharma Surgeen2026-08-03T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-4deeccc6c9da215cPharma Surgeen2026-08-03T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-d7794b0dd52bf2caPharma Surgeen2026-08-03T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-1ade2a6b702fa8e9Pharma Surgeen2026-08-03T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-48a2123bd9e68bf7Pharma Surgeen2026-08-03T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-a5a23f8ac9164326Pharma Surgeen2026-08-03T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/national-institute-of-allergy-and-infectious-diseases-notice-of-meeting-c8dc0a63ef1a8f63Pharma Surgeen2026-08-03T00:00:00.000ZNational Institute of Allergy and Infectious Diseases; Notice of Meetinghttps://www.pharmaradar360.com/article/national-institute-of-allergy-and-infectious-diseases-notice-of-meetings-df9179dd51c27d06Pharma Surgeen2026-08-03T00:00:00.000ZNational Institute of Allergy and Infectious Diseases; Notice of Meetingshttps://www.pharmaradar360.com/article/medicare-program-fy-2027-hospice-wage-index-and-payment-rate-update-and-hospice-bef5ad53a04e50b8Pharma Surgeen2026-08-03T00:00:00.000ZMedicare Program; FY 2027 Hospice Wage Index and Payment Rate Update and Hospice Quality Reporting Program Requirementshttps://www.pharmaradar360.com/article/national-institute-of-mental-health-notice-of-closed-meeting-082ef3c167dc2b67Pharma Surgeen2026-08-03T00:00:00.000ZNational Institute of Mental Health; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/reducing-bureaucracy-and-burden-in-family-violence-and-prevention-services-417b0a2da45a42d5Pharma Surgeen2026-08-03T00:00:00.000ZReducing Bureaucracy and Burden in Family Violence and Prevention Serviceshttps://www.pharmaradar360.com/article/national-center-for-advancing-translational-sciences-notice-of-meeting-c680d39aeda9a75bPharma Surgeen2026-08-03T00:00:00.000ZNational Center for Advancing Translational Sciences; Notice of Meetinghttps://www.pharmaradar360.com/article/modification-of-certain-terminology-in-title-21-reopening-of-the-comment-period-cb85bc368f0df9a2Pharma Surgeen2026-08-03T00:00:00.000ZModification of Certain Terminology in Title 21; Reopening of the Comment Periodhttps://www.pharmaradar360.com/article/medicare-program-inpatient-rehabilitation-facility-prospective-payment-system-fo-2a384ef76956c3eePharma Surgeen2026-08-03T00:00:00.000ZMedicare Program; Inpatient Rehabilitation Facility Prospective Payment System for Federal Fiscal Year 2027 and Updates to the IRF Quality Reporting Programhttps://www.pharmaradar360.com/article/current-list-of-hhs-certified-laboratories-and-instrumented-initial-testing-faci-3ca06ee144600e89Pharma Surgeen2026-08-03T00:00:00.000ZCurrent List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine and Oral Fluid Drug Testing for Federal Agencieshttps://www.pharmaradar360.com/article/ricardo-andres-acuna-final-debarment-order-7670ed85c0da5180Pharma Surgeen2026-08-03T00:00:00.000ZRicardo Andres Acuna: Final Debarment Orderhttps://www.pharmaradar360.com/article/angela-anatilde-baquero-final-debarment-order-4031c16e9a33a7eePharma Surgeen2026-08-03T00:00:00.000ZAngela Anatilde Baquero: Final Debarment Orderhttps://www.pharmaradar360.com/article/notice-regarding-340b-rebate-model-pilot-program-d552cd82ac9a888cPharma Surgeen2026-08-03T00:00:00.000ZNotice Regarding 340B Rebate Model Pilot Programhttps://www.pharmaradar360.com/article/biosimilar-and-interchangeable-biosimilar-products-considerations-for-container-02cc0a00e8743596Pharma Surgeen2026-08-03T00:00:00.000ZBiosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts; Draft Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/national-institute-of-nursing-research-notice-of-partially-closed-meeting-8ba45c53db8541f4Pharma Surgeen2026-08-03T00:00:00.000ZNational Institute of Nursing Research; Notice of Partially Closed Meetinghttps://www.pharmaradar360.com/article/national-institute-of-arthritis-and-musculoskeletal-and-skin-diseases-notice-of-0d93c6d075f0d015Pharma Surgeen2026-08-03T00:00:00.000ZNational Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Partially Closed Meetinghttps://www.pharmaradar360.com/article/national-institute-of-environmental-health-sciences-notice-of-partially-closed-m-1f5c5bde6809ff1bPharma Surgeen2026-08-03T00:00:00.000ZNational Institute of Environmental Health Sciences; Notice of Partially Closed Meetinghttps://www.pharmaradar360.com/article/amendment-to-3-4-mdp-2-p-methyl-glycidic-acid-a-list-i-chemical-2a883f1cb312536dPharma Surgeen2026-08-03T00:00:00.000ZAmendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemicalhttps://www.pharmaradar360.com/article/assessing-adhesion-with-transdermal-and-topical-delivery-systems-for-andas-guida-977a29b9dfcaa209Pharma Surgeen2026-08-03T00:00:00.000ZAssessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/assessing-the-irritation-and-sensitization-potential-of-transdermal-and-topical-c1e70688ec00e419Pharma Surgeen2026-08-03T00:00:00.000ZAssessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs; Revised Draft Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-to-omb-for-review-and-approv-93c3ccc4379e98f8Pharma Surgeen2026-08-03T00:00:00.000ZAgency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; National Health Service Corps Scholar/Students to Service Travel Worksheet, OMB No. 0906-0087-Revisionhttps://www.pharmaradar360.com/article/cleveland-clinic-launches-drone-delivery-program-for-prescription-medications-4935ee3205ba6466Pharma Surgeen2026-08-03T00:00:00.000ZCleveland Clinic Launches Drone Delivery Program for Prescription Medicationshttps://www.pharmaradar360.com/article/ai-identifies-previously-unrecognized-health-insights-in-routine-sleep-studies-6f65d9b45d6f11a6Pharma Surgeen2026-08-03T00:00:00.000ZAI Identifies Previously Unrecognized Health Insights in Routine Sleep Studieshttps://www.pharmaradar360.com/article/functional-vs-structural-renal-outcomes-of-sglt2-inhibitors-in-autosomal-dominan-dd05ab6737cf9afbPharma Surgeen2026-08-03T00:00:00.000ZFunctional vs Structural Renal Outcomes of SGLT2 Inhibitors in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review of Preclinical and Clinical Evidence.https://www.pharmaradar360.com/article/u-s-student-pharmacists-perspectives-on-the-pharmacogenomics-of-escitalopram-and-31e2dfb0ed8b77bbPharma Surgeen2026-08-03T00:00:00.000ZU.S. student pharmacists perspectives on the pharmacogenomics of escitalopram and aripiprazole.https://www.pharmaradar360.com/article/evaluation-of-the-antimicrobial-effect-of-silver-nanoparticles-incorporated-into-03028a2ef4408171Pharma Surgeen2026-08-03T00:00:00.000ZEvaluation of the Antimicrobial Effect of Silver Nanoparticles Incorporated Into Heat-Cured Acrylic Denture Base Resin: A Clinical Studyhttps://www.pharmaradar360.com/article/pharmacognostic-and-phytochemical-investigation-of-camellia-sinensis-for-anti-ob-7071dfd5c3354f30Pharma Surgeen2026-08-03T00:00:00.000ZPharmacognostic and Phytochemical Investigation of Camellia sinensis for Anti-Obesity Activity in Metabolic Syndromehttps://www.pharmaradar360.com/article/identification-of-polymorphic-ssr-markers-for-rapid-hybridity-confirmation-and-g-83b91d550db01c77Pharma Surgeen2026-08-03T00:00:00.000ZIdentification of Polymorphic SSR Markers for Rapid Hybridity Confirmation and Genetic Purity Assessment of Sunflower (Helianthus annuus L.) Hybrid KBSH-78https://www.pharmaradar360.com/article/character-association-and-path-coefficient-analysis-for-yield-yield-attributing-ca114748c8ac9cc6Pharma Surgeen2026-08-03T00:00:00.000ZCharacter Association and Path Coefficient Analysis for Yield, Yield Attributing and Oil Content Traits in Sesame (Sesamum indicum L.) Germplasmhttps://www.pharmaradar360.com/article/drug-induced-dysphagia-analysis-of-age-and-time-of-onset-profiles-using-a-japane-2292431fad5a7cd7Pharma Surgeen2026-08-03T00:00:00.000ZDrug-induced dysphagia: Analysis of age and time of onset profiles using a Japanese pharmacovigilance databasehttps://www.pharmaradar360.com/article/screen-time-exposure-sleep-alterations-and-their-relationship-with-excess-weight-cd25e22986fd3b04Pharma Surgeen2026-08-03T00:00:00.000ZScreen time exposure, sleep alterations, and their relationship with excess weight in children and adolescentshttps://www.pharmaradar360.com/article/prevalence-and-clinical-characteristics-of-pediatric-parasitic-gastroenteritis-w-63e844065eb639f7Pharma Surgeen2026-08-03T00:00:00.000ZPrevalence and Clinical Characteristics of Pediatric Parasitic Gastroenteritis with a Comparative Analysis of Diagnostic Methodshttps://www.pharmaradar360.com/article/a-growing-epidemic-of-loneliness-among-us-military-veterans-7edaeca79d55ede2Pharma Surgeen2026-08-03T00:00:00.000ZA Growing Epidemic of Loneliness Among US Military Veteranshttps://www.pharmaradar360.com/article/chrono-immunotherapy-in-genitourinary-oncology-from-emerging-evidence-to-clinica-6d25cdb5d39a08a3Pharma Surgeen2026-08-03T00:00:00.000ZChrono‑immunotherapy in genitourinary oncology: From emerging evidence to clinical translation (Review)https://www.pharmaradar360.com/article/reactive-oxygen-species-imbalance-in-atherosclerosis-biomarker-phenotyping-resid-6b95085de074a00aPharma Surgeen2026-08-03T00:00:00.000ZReactive oxygen species imbalance in atherosclerosis: Biomarker phenotyping, residual risk, and a translational framework for precision preventionhttps://www.pharmaradar360.com/article/hormetic-stress-responses-in-aging-from-molecular-mechanisms-to-clinical-transla-a3e688468fb386a4Pharma Surgeen2026-08-03T00:00:00.000ZHormetic Stress Responses in Aging: From Molecular Mechanisms to Clinical Translationhttps://www.pharmaradar360.com/article/environmental-and-clinical-spread-of-mdr-acinetobacter-baumannii-a-genomic-epide-4d54f443e5ecfbe9Pharma Surgeen2026-08-03T00:00:00.000ZEnvironmental and Clinical Spread of MDR Acinetobacter baumannii: A Genomic Epidemiology Investigationhttps://www.pharmaradar360.com/article/contemporary-surgical-tricuspid-valve-repair-17fa3be50c381cb6Pharma Surgeen2026-08-03T00:00:00.000ZContemporary Surgical Tricuspid Valve Repairhttps://www.pharmaradar360.com/article/clinical-utility-of-an-fda-authorized-artificial-intelligence-imaging-platform-i-dc4216fb2b39961ePharma Surgeen2026-08-03T00:00:00.000ZClinical Utility of an FDA-Authorized Artificial Intelligence Imaging Platform in Interstitial Lung Disease Diagnosishttps://www.pharmaradar360.com/article/clinical-and-epidemiological-landscape-of-antimicrobial-resistance-and-virulence-2226ccdb1c224388Pharma Surgeen2026-08-03T00:00:00.000ZClinical and Epidemiological Landscape of Antimicrobial Resistance and Virulence in Streptococcus Specieshttps://www.pharmaradar360.com/article/clinical-emergence-and-genomic-characterization-of-aztreonam-avibactam-resistant-6538480671b781c4Pharma Surgeen2026-08-03T00:00:00.000ZClinical Emergence and Genomic Characterization of Aztreonam–Avibactam-Resistant Escherichia coli ST410 Isolates in Chinahttps://www.pharmaradar360.com/article/association-of-intraoperative-cell-salvage-combined-with-standard-allogeneic-tra-af6fce8d0f4708cePharma Surgeen2026-08-03T00:00:00.000ZAssociation of intraoperative cell salvage combined with standard allogeneic transfusion with hematological parameters and clinical outcomes in pediatric tracheoplasty: a non-randomized cohort studyhttps://www.pharmaradar360.com/article/impact-of-evidence-based-nursing-on-clinical-outcomes-in-patients-with-leukemia-3f963159c4a6df49Pharma Surgeen2026-08-03T00:00:00.000ZImpact of evidence-based nursing on clinical outcomes in patients with leukemia undergoing chemotherapyhttps://www.pharmaradar360.com/article/comparison-of-the-efficacy-and-safety-of-nafamostat-mesylate-and-heparin-in-bloo-53f781c94a88cd71Pharma Surgeen2026-08-03T00:00:00.000ZComparison of the efficacy and safety of nafamostat mesylate and heparin in blood purification therapy for patients with severe acute pancreatitis: protocol for a randomized controlled trialhttps://www.pharmaradar360.com/article/molecular-sensitization-profiles-and-parvalbumin-sensitization-burden-associated-4b695003796471e6Pharma Surgeen2026-08-03T00:00:00.000ZMolecular sensitization profiles and β-parvalbumin sensitization burden associated with clinical fish allergy in childrenhttps://www.pharmaradar360.com/article/ultrathin-strut-drug-eluting-stents-are-associated-with-lower-revascularization-0cdf3b55c22531e4Pharma Surgeen2026-08-03T00:00:00.000ZUltrathin-strut drug-eluting stents are associated with lower revascularization rates than drug-coated balloons in non-focal in-stent restenosishttps://www.pharmaradar360.com/article/acute-acalculous-cholecystitis-in-dengue-fever-an-emerging-clinical-entity-87d2a2f80697be0cPharma Surgeen2026-08-03T00:00:00.000ZAcute Acalculous Cholecystitis in Dengue Fever: An Emerging Clinical Entityhttps://www.pharmaradar360.com/article/leucose-enzootica-bovina-em-rebanho-de-corte-da-regiao-metropolitana-do-recife-p-8aea799008015dc9Pharma Surgeen2026-08-03T00:00:00.000ZLEUCOSE ENZOÓTICA BOVINA EM REBANHO DE CORTE DA REGIÃO METROPOLITANA DO RECIFE, PERNAMBUCO: ASPECTOS CLÍNICOS, SOROLÓGICOS E ANATOMOPATOLÓGICOShttps://www.pharmaradar360.com/article/integration-of-ultrasound-electro-fenton-processes-for-total-organic-carbon-and-7fbf32de80e7787aPharma Surgeen2026-08-03T00:00:00.000ZIntegration of ultrasound-electro-Fenton processes for total organic carbon and inorganic carbon removal in pharmaceutical wastewaterhttps://www.pharmaradar360.com/article/stage-specific-comparative-effectiveness-of-diverting-stoma-as-a-bridge-to-surge-a84db9354ed751a0Pharma Surgeen2026-08-03T00:00:00.000ZStage-Specific Comparative Effectiveness of Diverting Stoma as a Bridge to Surgery Versus Emergency Resection for Obstructive Colorectal Cancer: A Nationwide Target Trial Emulationhttps://www.pharmaradar360.com/article/sonoreasoner-hierarchical-clinical-reasoning-for-ultrasound-vision-language-mode-64a292dcc7450c31Pharma Surgeen2026-08-03T00:00:00.000ZSonoReasoner: Hierarchical Clinical Reasoning for Ultrasound Vision-Language Modelshttps://www.pharmaradar360.com/article/longitudinal-changes-in-intracranial-eeg-spectral-power-and-phase-locking-value-b327487905a59b1fPharma Surgeen2026-08-03T00:00:00.000ZLongitudinal Changes in Intracranial EEG Spectral Power and Phase-Locking Value During Responsive Neurostimulation Therapy in Drug-Resistant Epilepsyhttps://www.pharmaradar360.com/article/tet2-downregulation-limits-oxidative-stress-induced-cytotoxicity-of-high-dose-as-2ab8b246c7f2d57dPharma Surgeen2026-08-03T00:00:00.000ZTET2 downregulation limits oxidative stress-induced cytotoxicity of high dose ascorbate in dabrafenib-resistant melanoma cellshttps://www.pharmaradar360.com/article/changes-in-bio-psycho-social-aspects-of-male-aging-a-comparative-study-of-hospit-9f83e0b9214c06dcPharma Surgeen2026-08-03T00:00:00.000ZChanges in bio-psycho-social aspects of male aging: A comparative study of hospitalized patients (2013–2023)https://www.pharmaradar360.com/article/clinical-significance-and-outcomes-of-left-sided-gallbladder-for-cholecystectomy-9992ae7de198f1afPharma Surgeen2026-08-03T00:00:00.000ZClinical significance and outcomes of left-sided gallbladder for cholecystectomy: A retrospective cohort study based on 12-year single-center experiencehttps://www.pharmaradar360.com/article/bridging-theory-and-practice-assessing-the-benefits-and-challenges-of-early-clin-1f312860714b2973Pharma Surgeen2026-08-03T00:00:00.000ZBridging Theory and Practice: Assessing the Benefits and Challenges of Early Clinical Exposure in Dental Educationhttps://www.pharmaradar360.com/article/research-progress-and-trends-on-epigenetics-and-endometriosis-a-bibliometric-ana-fbaabee4e45356b6Pharma Surgeen2026-08-03T00:00:00.000ZResearch progress and trends on epigenetics and endometriosis: a bibliometric analysishttps://www.pharmaradar360.com/article/an-exploratory-patient-specific-finite-element-study-of-temporomandibular-joint-5ed954182bca5eeePharma Surgeen2026-08-03T00:00:00.000ZAn exploratory patient-specific finite element study of temporomandibular joint stress distribution following mandibular setback surgery in two distinct clinical scenarioshttps://www.pharmaradar360.com/article/vital-pulp-therapy-or-root-canal-treatment-a-12-month-clinical-evaluation-follow-3977d6f17c6a63f5Pharma Surgeen2026-08-03T00:00:00.000ZVital pulp therapy or root canal treatment? A 12-month clinical evaluation following prosthetic pulp exposure: a retrospective cohort studyhttps://www.pharmaradar360.com/article/the-relationship-between-in-socket-mechanics-and-patient-reported-comfort-and-fu-b32d62866ca2414aPharma Surgeen2026-08-03T00:00:00.000ZThe relationship between in-socket mechanics and patient-reported comfort and function, a randomized crossover trialhttps://www.pharmaradar360.com/article/effect-of-motivational-interviews-and-peer-education-on-adherence-to-pre-exposur-e4d2f221fa0d3026Pharma Surgeen2026-08-03T00:00:00.000ZEffect of motivational interviews and peer education on adherence to pre-exposure prophylaxis among key populations in Kisangani: a randomized clinical trialhttps://www.pharmaradar360.com/article/effectiveness-of-recruitment-methods-in-cancer-clinical-trials-an-australian-exp-30fa0fa0faf6949cPharma Surgeen2026-08-03T00:00:00.000ZEffectiveness of recruitment methods in cancer clinical trials: an Australian experiencehttps://www.pharmaradar360.com/article/comparison-of-a-ketogenic-diet-and-nhs-healthy-eating-guidance-for-bipolar-depre-4f4b82e7650f5e26Pharma Surgeen2026-08-03T00:00:00.000ZComparison of a ketogenic diet and NHS healthy eating guidance for bipolar depression: a randomised controlled trialhttps://www.pharmaradar360.com/article/evaluating-a-gel-with-hyaluronic-acid-and-amino-acids-to-improve-bone-healing-af-7bcb7d1f1b1e1359Pharma Surgeen2026-08-03T00:00:00.000ZEvaluating a gel with hyaluronic acid and amino acids to improve bone healing after tooth extraction: a clinical studyhttps://www.pharmaradar360.com/article/express-evaluation-of-the-clinical-course-of-immune-mediated-polyneuropathy-in-c-6d24301c3462a052Pharma Surgeen2026-08-03T00:00:00.000ZEXPRESS: Evaluation of the clinical course of immune-mediated polyneuropathy in cats following treatment with human intravenous immunoglobulinshttps://www.pharmaradar360.com/article/diabetic-and-er-stressed-pancreatic-islet-cells-are-in-need-of-some-jnk-removal-488e86bf86899913Pharma Surgeen2026-08-03T00:00:00.000ZDiabetic and ER-stressed pancreatic islet β cells are in need of some JNK removalhttps://www.pharmaradar360.com/article/corrigendum-to-super-enhancer-driven-efna1-fuels-tumor-progression-in-cervical-c-b79bd4f3f0dfe596Pharma Surgeen2026-08-03T00:00:00.000ZCorrigendum to Super-enhancer–driven EFNA1 fuels tumor progression in cervical cancer via the FOSL2-Src/AKT/STAT3 axishttps://www.pharmaradar360.com/article/lymphatic-therapies-open-the-valve-in-marfan-syndrome-232d217917433c28Pharma Surgeen2026-08-03T00:00:00.000ZLymphatic therapies open the valve in Marfan syndromehttps://www.pharmaradar360.com/article/good-cop-bad-cop-rethinking-the-roles-of-cardiac-macrophages-in-injury-8419ee3101178e2fPharma Surgeen2026-08-03T00:00:00.000ZGood cop, bad cop? Rethinking the roles of cardiac macrophages in injuryhttps://www.pharmaradar360.com/article/lingo1-targeted-antibody-drug-conjugates-improve-efficacy-and-tolerability-of-an-b496d4d547d751e4Pharma Surgeen2026-08-03T00:00:00.000ZLINGO1-targeted antibody-drug conjugates improve efficacy and tolerability of antineoplastic therapies in Ewing sarcoma modelshttps://www.pharmaradar360.com/article/supplemental-table-1-from-simvastatin-treatment-in-patients-with-liver-cirrhosis-c4e2eb5660dd2ce2Pharma Surgeen2026-08-03T00:00:00.000ZSupplemental Table 1 from Simvastatin Treatment in Patients with Liver Cirrhosis: A Phase II Randomized Placebo-Controlled Trial Shows Reduction in IL6 Levelshttps://www.pharmaradar360.com/article/data-from-first-in-human-trial-of-encapsulated-cells-constitutively-expressing-l-480edefd769258c2Pharma Surgeen2026-08-03T00:00:00.000ZData from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinomahttps://www.pharmaradar360.com/article/figure-4-from-benralizumab-for-eosinophil-related-cutaneous-adverse-events-of-an-89cce52119eac6eePharma Surgeen2026-08-03T00:00:00.000ZFigure 4 from Benralizumab for Eosinophil-Related Cutaneous Adverse Events of Anticancer Therapy: A Phase II Trialhttps://www.pharmaradar360.com/article/table-2-from-benralizumab-for-eosinophil-related-cutaneous-adverse-events-of-ant-38f212222b315cb6Pharma Surgeen2026-08-03T00:00:00.000ZTable 2 from Benralizumab for Eosinophil-Related Cutaneous Adverse Events of Anticancer Therapy: A Phase II Trialhttps://www.pharmaradar360.com/article/supplementary-data-2-from-first-in-human-trial-of-encapsulated-cells-constitutiv-756670e953f8a872Pharma Surgeen2026-08-03T00:00:00.000ZSupplementary Data 2 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinomahttps://www.pharmaradar360.com/article/supplementary-figure-s3-from-first-in-human-trial-of-encapsulated-cells-constitu-7ff9191610bd8292Pharma Surgeen2026-08-03T00:00:00.000ZSupplementary Figure S3 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinomahttps://www.pharmaradar360.com/article/supplementary-figure-s5-from-first-in-human-trial-of-encapsulated-cells-constitu-be076a979de4601ePharma Surgeen2026-08-03T00:00:00.000ZSupplementary Figure S5 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinomahttps://www.pharmaradar360.com/article/supplementary-figure-s7-from-first-in-human-trial-of-encapsulated-cells-constitu-69a0d19dfb1d8139Pharma Surgeen2026-08-03T00:00:00.000ZSupplementary Figure S7 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinomahttps://www.pharmaradar360.com/article/supplementary-tables-1-10-from-first-in-human-trial-of-encapsulated-cells-consti-dce05d42a1f18399Pharma Surgeen2026-08-03T00:00:00.000ZSupplementary Tables 1-10 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinomahttps://www.pharmaradar360.com/article/supplementary-figure-s10-from-transcriptomic-insights-into-lobular-breast-cancer-567a228b6905e7acPharma Surgeen2026-08-03T00:00:00.000ZSupplementary Figure S10 from Transcriptomic Insights into Lobular Breast Cancer Biology and Patient Outcomes: Analysis of the MINDACT Clinical Trialhttps://www.pharmaradar360.com/article/supplementary-data-1-from-the-phase-ib-impact-trial-of-intramuscular-personalize-f0b85f4c0553a235Pharma Surgeen2026-08-03T00:00:00.000ZSupplementary Data 1 from The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinomahttps://www.pharmaradar360.com/article/supplementary-data-2-from-the-phase-ib-impact-trial-of-intramuscular-personalize-679f3331a787eff8Pharma Surgeen2026-08-03T00:00:00.000ZSupplementary Data 2 from The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinomahttps://www.pharmaradar360.com/article/supplementary-data-4-from-the-phase-ib-impact-trial-of-intramuscular-personalize-ffc0ccd9d47ddd52Pharma Surgeen2026-08-03T00:00:00.000ZSupplementary Data 4 from The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinomahttps://www.pharmaradar360.com/article/supplementary-figures-s1-s19-from-phenotypic-and-functional-characteristics-of-c-83e9d92d463153c6Pharma Surgeen2026-08-03T00:00:00.000ZSupplementary Figures S1-S19 from Phenotypic and Functional Characteristics of CD8<sup>+</sup> T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanomahttps://www.pharmaradar360.com/article/supplementary-table-4-from-phase-i-trial-of-ipatasertib-plus-atezolizumab-enhanc-f3ed3ccb0ff9a4fePharma Surgeen2026-08-03T00:00:00.000ZSupplementary Table 4 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastomahttps://www.pharmaradar360.com/article/supplementary-table-s1-from-nivolumab-and-ipilimumab-combination-treatment-in-pa-8fb59282f5deb77fPharma Surgeen2026-08-03T00:00:00.000ZSupplementary Table S1 from Nivolumab and Ipilimumab Combination Treatment in Patients with Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: Results from the Phase II MoST-CIRCUIT Trialhttps://www.pharmaradar360.com/article/dna-sequencing-for-microbial-surveillance-in-cystic-fibrosis-airways-advances-ch-a0b05af06777faacPharma Surgeen2026-08-03T00:00:00.000ZDNA sequencing for microbial surveillance in cystic fibrosis airways: advances, challenges, and clinical translationhttps://www.pharmaradar360.com/article/source-localization-of-subclinical-rhythmic-eeg-discharge-of-adult-using-magneto-c97b557be3ffc14fPharma Surgeen2026-08-03T00:00:00.000ZSource Localization of Subclinical Rhythmic EEG Discharge of Adult Using Magnetoencephalographyhttps://www.pharmaradar360.com/article/letter-to-the-editor-cc58220ead4662e3Pharma Surgeen2026-08-03T00:00:00.000ZLetter to the Editorhttps://www.pharmaradar360.com/article/recurrent-external-ventricular-drain-associated-ventriculitis-due-to-multidrug-r-5e8d03f7c45128aaPharma Surgeen2026-08-03T00:00:00.000ZRecurrent External Ventricular Drain–Associated Ventriculitis due to Multidrug-Resistant Acinetobacter baumannii in 2 Siblingshttps://www.pharmaradar360.com/article/variables-associated-with-prescription-opioid-misuse-in-individuals-with-chronic-3449e9e13547da73Pharma Surgeen2026-08-03T00:00:00.000ZVariables Associated with Prescription Opioid Misuse in Individuals with Chronic Noncancer Painhttps://www.pharmaradar360.com/article/integrated-clinical-genetic-pathological-analysis-expands-the-phenotypic-and-mol-365b75d65b06b3fbPharma Surgeen2026-08-03T00:00:00.000ZIntegrated Clinical–Genetic–Pathological Analysis Expands the Phenotypic and Molecular Spectrum of PPNAD Across Carney Complex and Isolated Formshttps://www.pharmaradar360.com/article/profiling-the-pattern-of-medication-use-during-pregnancy-an-international-scopin-a44a6d2de5a98f04Pharma Surgeen2026-08-03T00:00:00.000ZProfiling the pattern of medication use during pregnancy: an international scoping review of observational studieshttps://www.pharmaradar360.com/article/ai-enabled-ehr-mining-of-sbdoh-enables-diverse-trial-recruitment-but-raises-ethi-af8d24a9a42d1435Pharma Surgeen2026-08-03T00:00:00.000ZAI-Enabled EHR Mining of SBDOH Enables Diverse Trial Recruitment but Raises Ethical Concernshttps://www.pharmaradar360.com/article/recruitment-inference-creep-why-ai-in-clinical-trials-needs-auditable-ethical-li-772b29fefc6a7381Pharma Surgeen2026-08-03T00:00:00.000ZRecruitment Inference Creep: Why AI in Clinical Trials Needs Auditable Ethical Limitshttps://www.pharmaradar360.com/article/selinexor-combined-bortezomib-lenalidomide-and-dexamethasone-for-newly-diagnosed-89e59ecdfee3fff5Pharma Surgeen2026-08-03T00:00:00.000ZSelinexor combined bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with high-risk factors: a single-arm, multi-center, prospective observational clinical studyhttps://www.pharmaradar360.com/article/speech-intelligibility-depends-on-listener-experience-comparing-speech-language-752e1caa0dd5802ePharma Surgeen2026-08-03T00:00:00.000ZSpeech intelligibility depends on listener experience: Comparing speech-language pathologists, naïve listeners, and automated recognitionhttps://www.pharmaradar360.com/article/development-and-field-evaluation-of-an-indonesian-speech-perception-assessment-f-41a82b9c98b5c591Pharma Surgeen2026-08-03T00:00:00.000ZDevelopment and field evaluation of an Indonesian speech perception assessment for children with severe to profound hearing losshttps://www.pharmaradar360.com/article/effects-of-blood-flow-restriction-augmented-baduanjin-training-on-quadriceps-str-031fc2167677479bPharma Surgeen2026-08-03T00:00:00.000ZEffects of blood flow restriction–augmented baduanjin training on quadriceps strength and postural stability in sedentary young men: a randomized controlled trialhttps://www.pharmaradar360.com/article/cancer-drug-response-and-resistance-molecular-mechanisms-and-combating-strategie-2523ffad42ef6013Pharma Surgeen2026-08-03T00:00:00.000ZCancer drug response and resistance: molecular mechanisms and combating strategieshttps://www.pharmaradar360.com/article/impact-of-3-day-turmeric-supplementation-on-fasting-and-postprandial-lps-and-chy-843b3b6e5a6c9038Pharma Surgeen2026-08-03T00:00:00.000ZImpact of 3-day turmeric supplementation on fasting and postprandial LPS and chylomicron-related markers in patients with IBS: A randomized crossover trial.https://www.pharmaradar360.com/article/clinical-outcomes-after-week-12-response-guided-secukinumab-discontinuation-in-p-5ed5a159aa14b4acPharma Surgeen2026-08-03T00:00:00.000ZClinical Outcomes After Week-12 Response-Guided Secukinumab Discontinuation in Psoriasis: A Prospective Real-World Cohort Studyhttps://www.pharmaradar360.com/article/isoquercitrin-suppresses-neuronal-ferroptosis-in-ischemic-stroke-via-sirt1-media-87745ae7ed2d15e7Pharma Surgeen2026-08-03T00:00:00.000ZIsoquercitrin suppresses neuronal ferroptosis in ischemic stroke via SIRT1-mediated deacetylation of H3K9 at the RBM15 promoterhttps://www.pharmaradar360.com/article/maintenance-of-clinical-remission-with-cyclosporine-after-discontinuation-of-pre-ba7e448a73304d58Pharma Surgeen2026-08-03T00:00:00.000ZMaintenance of clinical remission with cyclosporine after discontinuation of prednisolone in a patient with tubulointerstitial nephritis with IgM-positive plasma cellshttps://www.pharmaradar360.com/article/novel-fast-dissolving-microneedle-patch-for-transdermal-delivery-of-granisetron-0a7b31c54a0144b6Pharma Surgeen2026-08-03T00:00:00.000ZNovel Fast Dissolving Microneedle Patch for Transdermal Delivery of Granisetron; Optimization, In-Vitro and Ex-Vivo Evaluationhttps://www.pharmaradar360.com/article/cas12a-crrna-recognition-catalyzed-triple-self-priming-cascade-amplification-str-52feae37e9f45103Pharma Surgeen2026-08-03T00:00:00.000ZCas12a/crRNA Recognition Catalyzed Triple Self-Priming Cascade Amplification Strategy for Sensitive and Reliable Drug Resistance Gene Analysishttps://www.pharmaradar360.com/article/integrative-molecular-epidemiology-of-sporothrix-in-latin-america-reveals-calmod-e0239235e8f28051Pharma Surgeen2026-08-03T00:00:00.000ZIntegrative molecular epidemiology of Sporothrix in Latin America reveals calmodulin genotypes associated with host, clinical form and geographic distributionhttps://www.pharmaradar360.com/article/early-effects-of-communities-that-care-on-system-transformation-a-non-randomized-c41024c33f812977Pharma Surgeen2026-08-03T00:00:00.000ZEarly Effects of Communities That Care on System Transformation: a Non-randomized Community Trial in Germanyhttps://www.pharmaradar360.com/article/applicability-and-reliability-of-the-iddsi-functional-diet-scale-iddsi-fds-in-cl-2e0b4d70dd6e047dPharma Surgeen2026-08-03T00:00:00.000ZApplicability and reliability of the IDDSI functional diet scale (IDDSI-FDS) in clinical reports of patients with oropharyngeal dysphagiahttps://www.pharmaradar360.com/article/application-of-multi-technique-integration-in-the-prenatal-diagnosis-of-mosaicis-0fda1f054a0222c1Pharma Surgeen2026-08-03T00:00:00.000ZApplication of multi-technique integration in the prenatal diagnosis of mosaicism derived from an ICSI blastocyst: a diagnostic approach and clinical implicationshttps://www.pharmaradar360.com/article/spiradenocarcinoma-a-systematic-review-of-clinical-features-diagnosis-and-highli-ebd277c581ed8b15Pharma Surgeen2026-08-03T00:00:00.000ZSpiradenocarcinoma: a systematic review of clinical features, diagnosis, and highlighting surgical management of a rare malignant cutaneous adnexal tumorhttps://www.pharmaradar360.com/article/the-academic-movement-disorders-neurologist-workforce-in-the-united-states-purpo-e76050b51577deadPharma Surgeen2026-08-03T00:00:00.000ZThe Academic Movement Disorders Neurologist Workforce in the United States: Purpose, Practice, and the Pursuit of Academic Satisfactionhttps://www.pharmaradar360.com/article/introduction-to-trial-level-subgroup-analysis-a-tutorial-b642fedf37724c88Pharma Surgeen2026-08-03T00:00:00.000ZIntroduction to Trial‐Level Subgroup Analysis: A Tutorialhttps://www.pharmaradar360.com/article/clinical-heterogeneity-and-long-term-outcomes-of-pediatric-gastrointestinal-stro-9ba39789e48b4e7fPharma Surgeen2026-08-03T00:00:00.000ZClinical Heterogeneity and Long‐Term Outcomes of Pediatric Gastrointestinal Stromal Tumors: A Series of Four Patients Highlighting SDH‐Deficient and SDH‐Intact Subtypeshttps://www.pharmaradar360.com/article/nct07743346-a-structured-nurse-led-empowerment-program-to-improve-knowledge-prac-4940f0b7040880cbPharma Surgeen2026-08-03T00:00:00.000ZNCT07743346: A Structured Nurse-Led Empowerment Program to Improve Knowledge, Practical Skills, and Self-Care Behaviours in Patients Living With a Permanent Pacemakerhttps://www.pharmaradar360.com/article/nct07743320-evaluating-the-effectiveness-of-an-ai-powered-physician-assistant-in-f6a77a4fa46e6b26Pharma Surgeen2026-08-03T00:00:00.000ZNCT07743320: Evaluating the Effectiveness of an AI-Powered Physician Assistant in Improving Patients' and Physicians' Satisfaction in Anaesthesiology Clinicshttps://www.pharmaradar360.com/article/nct07743034-iris-structural-changes-with-tamsulosin-vs-silodosin-in-benign-prost-fc0139db548fe237Pharma Surgeen2026-08-03T00:00:00.000ZNCT07743034: Iris Structural Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patientshttps://www.pharmaradar360.com/article/nct07742956-phase-ii-clinical-study-to-evaluate-the-safety-tolerability-pharmaco-852e2282ecfddde3Pharma Surgeen2026-08-03T00:00:00.000ZNCT07742956: Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants.https://www.pharmaradar360.com/article/nct07742709-study-on-the-rapid-diagnostic-value-of-sudden-clap-provocation-test-19937c7448aec2a2Pharma Surgeen2026-08-03T00:00:00.000ZNCT07742709: Study on the Rapid Diagnostic Value of Sudden Clap Provocation Test in Psychogenic Nonepileptic Seizureshttps://www.pharmaradar360.com/article/nct07742644-a-study-on-the-immune-response-and-safety-of-an-investigational-comb-26d7020916a23cb1Pharma Surgeen2026-08-03T00:00:00.000ZNCT07742644: A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Agehttps://www.pharmaradar360.com/article/nct07742605-a-clinical-trial-to-evaluate-the-effects-of-a-supplement-on-cognitiv-8c4fa898c96ee632Pharma Surgeen2026-08-03T00:00:00.000ZNCT07742605: A Clinical Trial to Evaluate the Effects of a Supplement on Cognitive Performancehttps://www.pharmaradar360.com/article/nct07742410-the-fecal-immunoassay-occult-blood-test-combined-with-calprotectin-s-c69d95396f9043ffPharma Surgeen2026-08-03T00:00:00.000ZNCT07742410: The Fecal Immunoassay Occult Blood Test Combined With Calprotectin Sequential Linkage Imaging Endoscopy Screening Strategy for Monitoring Tumor Changes Associated With Long-duration Ulcerative Colitishttps://www.pharmaradar360.com/article/nct07741877-a-study-of-lifileucel-tumor-infiltrating-lymphocytes-in-adults-with-18c60d6f848db040Pharma Surgeen2026-08-03T00:00:00.000ZNCT07741877: A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma